Cullen/Frost Bankers’s Maravai LifeSciences MRVI Stock Holding History

Cullen/Frost Bankers’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5	Closed	–	–	1165
2022 Q3	$0	Buy	+5	New	+$125	﹤0.01%	1172

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Cullen/Frost Bankers's MRVI Position: Q4 2022 in Review

Cullen/Frost Bankers sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 5 shares.

Cullen/Frost Bankers first reported a position in MRVI in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

Cullen/Frost Bankers reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
Cullen/Frost Bankers sold 5 Maravai LifeSciences shares in Q4 2022.
Cullen/Frost Bankers first reported a position in Maravai LifeSciences in Q3 2022 and held it in 1 quarter.
Cullen/Frost Bankers's Maravai LifeSciences position peaked at $0 in Q3 2022.
212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Cullen/Frost Bankers's 13F filing for Q4 2022, filed 13 Feb 2023.